122 related articles for article (PubMed ID: 36007768)
1. Synergistic targeting of the PI3K/mTOR and MAPK/ERK pathways in Merkel cell carcinoma.
Temblador A; Topalis D; Andrei G; Snoeck R
Tumour Virus Res; 2022 Dec; 14():200244. PubMed ID: 36007768
[TBL] [Abstract][Full Text] [Related]
2. Dual mTOR inhibitor MLN0128 suppresses Merkel cell carcinoma (MCC) xenograft tumor growth.
Kannan A; Lin Z; Shao Q; Zhao S; Fang B; Moreno MA; Vural E; Stack BC; Suen JY; Kannan K; Gao L
Oncotarget; 2016 Feb; 7(6):6576-92. PubMed ID: 26536665
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of PI3K by copanlisib exerts potent antitumor effects on Merkel cell carcinoma cell lines and mouse xenografts.
Fang B; Kannan A; Zhao S; Nguyen QH; Ejadi S; Yamamoto M; Camilo Barreto J; Zhao H; Gao L
Sci Rep; 2020 Jun; 10(1):8867. PubMed ID: 32483262
[TBL] [Abstract][Full Text] [Related]
4. Merkel cell polyomavirus-negative Merkel cell carcinoma is associated with JAK-STAT and MEK-ERK pathway activation.
Iwasaki T; Hayashi K; Matsushita M; Nonaka D; Kohashi K; Kuwamoto S; Umekita Y; Oda Y
Cancer Sci; 2022 Jan; 113(1):251-260. PubMed ID: 34724284
[TBL] [Abstract][Full Text] [Related]
5. Comparison of Akt/mTOR/4E-BP1 pathway signal activation and mutations of PIK3CA in Merkel cell polyomavirus-positive and Merkel cell polyomavirus-negative carcinomas.
Iwasaki T; Matsushita M; Nonaka D; Kuwamoto S; Kato M; Murakami I; Nagata K; Nakajima H; Sano S; Hayashi K
Hum Pathol; 2015 Feb; 46(2):210-6. PubMed ID: 25466966
[TBL] [Abstract][Full Text] [Related]
6. Activation of PI3K signaling in Merkel cell carcinoma.
Nardi V; Song Y; Santamaria-Barria JA; Cosper AK; Lam Q; Faber AC; Boland GM; Yeap BY; Bergethon K; Scialabba VL; Tsao H; Settleman J; Ryan DP; Borger DR; Bhan AK; Hoang MP; Iafrate AJ; Cusack JC; Engelman JA; Dias-Santagata D
Clin Cancer Res; 2012 Mar; 18(5):1227-36. PubMed ID: 22261808
[TBL] [Abstract][Full Text] [Related]
7. The effect of GP-2250 on cultured virus-negative Merkel cell carcinoma cells: preliminary results.
Gambichler T; Majchrzak-Stiller B; Peters I; Becker JC; Strotmann J; Abu Rached N; Müller T; Uhl W; Buchholz M; Braumann C
J Cancer Res Clin Oncol; 2023 Sep; 149(12):10831-10840. PubMed ID: 37311987
[TBL] [Abstract][Full Text] [Related]
8. Chronic mTOR activation promotes cell survival in Merkel cell carcinoma.
Lin Z; McDermott A; Shao L; Kannan A; Morgan M; Stack BC; Moreno M; Davis DA; Cornelius LA; Gao L
Cancer Lett; 2014 Mar; 344(2):272-281. PubMed ID: 24262658
[TBL] [Abstract][Full Text] [Related]
9. Tumor cell-intrinsic PD-1 promotes Merkel cell carcinoma growth by activating downstream mTOR-mitochondrial ROS signaling.
Martins C; Rasbach E; Heppt MV; Singh P; Kulcsar Z; Holzgruber J; Chakraborty A; Mucciarone K; Kleffel S; Brandenburg A; Hoetzenecker W; Rahbari NN; DeCaprio JA; Thakuria M; Murphy GF; Ramsey MR; Posch C; Barthel SR; Schatton T
Sci Adv; 2024 Jan; 10(3):eadi2012. PubMed ID: 38241371
[TBL] [Abstract][Full Text] [Related]
10. Synergistic inhibition of ovarian cancer cell growth by combining selective PI3K/mTOR and RAS/ERK pathway inhibitors.
Sheppard KE; Cullinane C; Hannan KM; Wall M; Chan J; Barber F; Foo J; Cameron D; Neilsen A; Ng P; Ellul J; Kleinschmidt M; Kinross KM; Bowtell DD; Christensen JG; Hicks RJ; Johnstone RW; McArthur GA; Hannan RD; Phillips WA; Pearson RB
Eur J Cancer; 2013 Dec; 49(18):3936-44. PubMed ID: 24011934
[TBL] [Abstract][Full Text] [Related]
11. Low-dose triple drug combination targeting the PI3K/AKT/mTOR pathway and the MAPK pathway is an effective approach in ovarian clear cell carcinoma.
Caumanns JJ; van Wijngaarden A; Kol A; Meersma GJ; Jalving M; Bernards R; van der Zee AGJ; Wisman GBA; de Jong S
Cancer Lett; 2019 Oct; 461():102-111. PubMed ID: 31319139
[TBL] [Abstract][Full Text] [Related]
12. Current and preclinical treatment options for Merkel cell carcinoma.
Celikdemir B; Houben R; Kervarrec T; Samimi M; Schrama D
Expert Opin Biol Ther; 2023; 23(10):1015-1034. PubMed ID: 37691397
[TBL] [Abstract][Full Text] [Related]
13. Multidisciplinary Treatment, Including Locoregional Chemotherapy, for Merkel-Polyomavirus-Positive Merkel Cell Carcinomas: Perspectives for Patients Exhibiting Oncogenic Alternative Δ exon 6-7 TrkAIII Splicing of Neurotrophin Receptor Tropomyosin-Related Kinase A.
Guadagni S; Farina AR; Cappabianca LA; Sebastiano M; Maccarone R; Zelli V; Clementi M; Chiominto A; Bruera G; Ricevuto E; Fiorentini G; Sarti D; Mackay AR
Int J Mol Sci; 2020 Nov; 21(21):. PubMed ID: 33153070
[TBL] [Abstract][Full Text] [Related]
14. PI-103 and sorafenib inhibit hepatocellular carcinoma cell proliferation by blocking Ras/Raf/MAPK and PI3K/AKT/mTOR pathways.
Gedaly R; Angulo P; Hundley J; Daily MF; Chen C; Koch A; Evers BM
Anticancer Res; 2010 Dec; 30(12):4951-8. PubMed ID: 21187475
[TBL] [Abstract][Full Text] [Related]
15. Characterization of six Merkel cell polyomavirus-positive Merkel cell carcinoma cell lines: Integration pattern suggest that large T antigen truncating events occur before or during integration.
Schrama D; Sarosi EM; Adam C; Ritter C; Kaemmerer U; Klopocki E; König EM; Utikal J; Becker JC; Houben R
Int J Cancer; 2019 Aug; 145(4):1020-1032. PubMed ID: 30873613
[TBL] [Abstract][Full Text] [Related]
16. Activation of the PI3K/AKT pathway in Merkel cell carcinoma.
Hafner C; Houben R; Baeurle A; Ritter C; Schrama D; Landthaler M; Becker JC
PLoS One; 2012; 7(2):e31255. PubMed ID: 22363598
[TBL] [Abstract][Full Text] [Related]
17. PKI-587 and sorafenib targeting PI3K/AKT/mTOR and Ras/Raf/MAPK pathways synergistically inhibit HCC cell proliferation.
Gedaly R; Angulo P; Hundley J; Daily MF; Chen C; Evers BM
J Surg Res; 2012 Aug; 176(2):542-8. PubMed ID: 22261591
[TBL] [Abstract][Full Text] [Related]
18. Polyomavirus-Positive Merkel Cell Carcinoma Derived from a Trichoblastoma Suggests an Epithelial Origin of this Merkel Cell Carcinoma.
Kervarrec T; Aljundi M; Appenzeller S; Samimi M; Maubec E; Cribier B; Deschamps L; Sarma B; Sarosi EM; Berthon P; Levy A; Bousquet G; Tallet A; Touzé A; Guyétant S; Schrama D; Houben R
J Invest Dermatol; 2020 May; 140(5):976-985. PubMed ID: 31759946
[TBL] [Abstract][Full Text] [Related]
19. Synthetic lethal interaction between PI3K/Akt/mTOR and Ras/MEK/ERK pathway inhibition in rhabdomyosarcoma.
Guenther MK; Graab U; Fulda S
Cancer Lett; 2013 Sep; 337(2):200-9. PubMed ID: 23684925
[TBL] [Abstract][Full Text] [Related]
20. Synergistic targeted inhibition of MEK and dual PI3K/mTOR diminishes viability and inhibits tumor growth of canine melanoma underscoring its utility as a preclinical model for human mucosal melanoma.
Wei BR; Michael HT; Halsey CH; Peer CJ; Adhikari A; Dwyer JE; Hoover SB; El Meskini R; Kozlov S; Weaver Ohler Z; Figg WD; Merlino G; Simpson RM
Pigment Cell Melanoma Res; 2016 Nov; 29(6):643-655. PubMed ID: 27463366
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]